FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:258-265 July 19, 2007 Number 3 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text PowerPoint Slide Set Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion of the clinical problem and the mechanism of benefit of this form of therapy follows. Major clinical studies, the clinical use of this therapy, and potential adverse effects are reviewed. Relevant formal guidelines, if they exist, are presented. The article ends with the author's clinical recommendations.

A 28-year-old woman is referred for advice about the management of recently diagnosed chronic myelogenous leukemia (CML). She was in excellent overall health but was incidentally found to have an elevated white-cell count of 31,000 per cubic millimeter. Bone . . . [Full Text of this Article]

The Clinical Problem

Pathophysiology and Effect of Therapy

Clinical Evidence

Clinical Use

Adverse Effects

Areas of Uncertainty

Guidelines

Recommendations

Source Information

From the Division of Hematology/Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit.

Address reprint requests to Dr. Schiffer at the Division of Hematology/Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, HWCRB 4th Fl., 4100 John R, Detroit, MI 48201, or at schiffer@karmanos.org.

Related Letters:

Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia
Defuentes G., Bladé J.-S., Berets O., Quintás-Cardama A., Kantarjian H., Cortes J., Schiffer C. A.
Extract | Full Text | PDF  
N Engl J Med 2007; 357:1556-1558, Oct 11, 2007. Correspondence

This article has been cited by other articles:

• Gratacap, M.-P., Martin, V., Valera, M.-C., Allart, S., Garcia, C., Sie, P., Recher, C., Payrastre, B. (2009). The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. Blood 114: 1884-1892 [Abstract] [Full Text]  
• Bodo, J., Durkin, L., Hsi, E. D. (2009). Quantitative In Situ Detection of Phosphoproteins in Fixed Tissues Using Quantum Dot Technology. J. Histochem. Cytochem. 57: 701-708 [Abstract] [Full Text]  
• Brehme, M., Hantschel, O., Colinge, J., Kaupe, I., Planyavsky, M., Kocher, T., Mechtler, K., Bennett, K. L., Superti-Furga, G. (2009). Charting the molecular network of the drug target Bcr-Abl. Proc. Natl. Acad. Sci. USA 106: 7414-7419 [Abstract] [Full Text]  
• Vannucchi, A. M., Guglielmelli, P., Tefferi, A. (2009). Advances in Understanding and Management of Myeloproliferative Neoplasms. CA Cancer J Clin 59: 171-191 [Abstract] [Full Text]  
• Zhang, Q.-Y., Mao, J.-H., Liu, P., Huang, Q.-H., Lu, J., Xie, Y.-Y., Weng, L., Zhang, Y., Chen, Q., Chen, S.-J., Chen, Z. (2009). A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia. Proc. Natl. Acad. Sci. USA 106: 3378-3383 [Abstract] [Full Text]  
• de Oliveira, R. A., Marques, I. D. B., Seguro, A. C., Andrade, L. (2009). Electrolyte disturbances and acute kidney injury induced by imatinib therapy. NDT Plus 2: 27-29 [Abstract] [Full Text]  
• Zhao, R., Follows, G. A., Beer, P. A., Scott, L. M., Huntly, B. J.P., Green, A. R., Alexander, D. R. (2008). Inhibition of the Bcl-xL Deamidation Pathway in Myeloproliferative Disorders. NEJM 359: 2778-2789 [Abstract] [Full Text]  
• Jonsson, S., Olsson, B., Ohlsson, C., Lorentzon, M., Mellstrom, D., Wadenvik, H. (2008). Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia. haematol 93: 1101-1103 [Full Text]  
• Shattuck, D. L., Miller, J. K., Carraway, K. L. III, Sweeney, C. (2008). Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells. Cancer Res. 68: 1471-1477 [Abstract] [Full Text]  
• Kuller, L. (2007). Is Phenomenology the Best Approach to Health Research?. Am J Epidemiol 166: 1109-1115 [Abstract] [Full Text]  
• Defuentes, G., Blade, J.-S., Berets, O., Quintas-Cardama, A., Kantarjian, H., Cortes, J., Schiffer, C. A. (2007). Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia. NEJM 357: 1556-1558 [Full Text]